MCID: PNL001
MIFTS: 14

Pineal Gland Astrocytoma

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pineal Gland Astrocytoma

MalaCards integrated aliases for Pineal Gland Astrocytoma:

Name: Pineal Gland Astrocytoma 12 71
Pineal Astrocytic Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4858
NCIt 49 C8274
UMLS 71 C0280795

Summaries for Pineal Gland Astrocytoma

MalaCards based summary : Pineal Gland Astrocytoma, also known as pineal astrocytic tumor, is related to low-grade astrocytoma. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include pineal, brain and t cells.

Related Diseases for Pineal Gland Astrocytoma

Diseases related to Pineal Gland Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1, show less)
# Related Disease Score Top Affiliating Genes
1 low-grade astrocytoma 10.1

Symptoms & Phenotypes for Pineal Gland Astrocytoma

Drugs & Therapeutics for Pineal Gland Astrocytoma

Drugs for Pineal Gland Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 83, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Analgesics Phase 3
4 Anesthetics Phase 3
5 Narcotics Phase 3
6 Cola Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics, General Phase 3
9 Liver Extracts Phase 3
10 Anesthetics, Intravenous Phase 3
11
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
12
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
13
Levetiracetam Approved Phase 2 102767-28-2 441341
14
Sodium citrate Approved, Investigational Phase 2 68-04-2
15
Tamoxifen Approved Phase 2 10540-29-1 2733526
16
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
17
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
18
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3
20
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
21
Promethazine Approved, Investigational Phase 2 60-87-7 4927
22
Acetaminophen Approved Phase 2 103-90-2 1983
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
24
Iodine Approved, Investigational Phase 2 7553-56-2 807
25
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
26
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
28
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
29 Alkylating Agents Phase 2
30 Hormones Phase 2
31 Psychotropic Drugs Phase 2
32 Anti-Anxiety Agents Phase 2
33 Anticonvulsants Phase 2
34 Calcium, Dietary Phase 2
35 calcium channel blockers Phase 2
36 Antineoplastic Agents, Hormonal Phase 2
37 Estrogen Antagonists Phase 2
38 Hormone Antagonists Phase 2
39 Citrate Phase 2
40 Estrogen Receptor Modulators Phase 2
41 topoisomerase I inhibitors Phase 2
42 Estrogens Phase 2
43 Estrogen Receptor Antagonists Phase 2
44 Angiogenesis Inhibitors Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 Central Nervous System Stimulants Phase 2
47 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
48 Antibodies Phase 2
49 Antibodies, Monoclonal Phase 2
50 Immunologic Factors Phase 2
51 Immunoglobulins Phase 2
52 cadexomer iodine Phase 2
53
Calcium Nutraceutical Phase 2 7440-70-2 271
54
Verteporfin Approved, Investigational Phase 1 129497-78-5
55
Trioxsalen Approved Phase 1 3902-71-4 5585
56
Hydroxyurea Approved Phase 1 127-07-1 3657
57
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
58
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093
59
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166
60
Vinblastine Approved Phase 1 865-21-4 241903 13342
61
Lonafarnib Investigational Phase 1 193275-84-2 148195
62
Vatalanib Investigational Phase 1 212141-54-3 151194
63 Dihematoporphyrin Ether Phase 1
64 Photosensitizing Agents Phase 1
65 Dermatologic Agents Phase 1
66 Protein Kinase Inhibitors Phase 1
67 Imatinib Mesylate Phase 1 220127-57-1 123596
68 Analgesics, Non-Narcotic Phase 1
69 glucocorticoids Phase 1
70 Anti-HIV Agents Phase 1
71 Anti-Infective Agents Phase 1
72 Interleukin-2 Phase 1
73 Anti-Retroviral Agents Phase 1
74 Antiviral Agents Phase 1
75 Interferon alpha-2 Phase 1
76 Antimony Sodium Gluconate Phase 1
77 interferons Phase 1
78 Anthelmintics Phase 1
79 Interferon-alpha Phase 1
80 Antiprotozoal Agents Phase 1
81 Tubulin Modulators Phase 1
82 Antiparasitic Agents Phase 1
83 Antimitotic Agents Phase 1

Interventional clinical trials:

(showing 23, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma Completed NCT00313729 Phase 2 temozolomide
3 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
4 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
5 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
6 Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00352521 Phase 2 bevacizumab;irinotecan
7 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
8 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
9 Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial Completed NCT01164189 Phase 2 Temozolomide
10 A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
11 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
12 Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
13 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
14 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
15 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
16 Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib
17 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
18 Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones Completed NCT00730613 Phase 1
19 Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
20 Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis Completed NCT00967200
21 CD4 Count And Risk Of Infection In Patients With Brain Tumors Completed NCT00999622
22 San Francisco Bay Area Adult Glioma Prognosis Study Protocol Completed NCT01009307
23 A Pharmacokinetic and Pharmacogenomic Study of Patients With High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide Terminated NCT00471653 temozolomide

Search NIH Clinical Center for Pineal Gland Astrocytoma

Genetic Tests for Pineal Gland Astrocytoma

Anatomical Context for Pineal Gland Astrocytoma

MalaCards organs/tissues related to Pineal Gland Astrocytoma:

40
Pineal, Brain, T Cells, Bone, Spinal Cord, Liver

Publications for Pineal Gland Astrocytoma

Variations for Pineal Gland Astrocytoma

Expression for Pineal Gland Astrocytoma

Search GEO for disease gene expression data for Pineal Gland Astrocytoma.

Pathways for Pineal Gland Astrocytoma

GO Terms for Pineal Gland Astrocytoma

Sources for Pineal Gland Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....